Details of the Drug Combination

General Information of Drug Combination (ID: DCH63Z4)

Drug Combination Name
Celecoxib Moxifloxacin
Indication
Disease Entry Status REF
Qt Interval, Variation in Phase 1 [1]
Component Drugs Celecoxib   DM6LOQU Moxifloxacin   DMU8V4S
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Celecoxib
Disease Entry ICD 11 Status REF
Dysmenorrhea GA34.3 Approved [2]
Lung cancer 2C25.0 Approved [2]
Osteoarthritis FA00-FA05 Approved [2]
Rheumatoid arthritis FA20 Approved [3]
Pain MG30-MG3Z Phase 3 [3]
Colon cancer 2B90.Z Investigative [2]
Familial adenomatous polyposis 2B90.Y Investigative [2]
Precancerous condition N.A. Investigative [2]
Celecoxib Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Prostaglandin G/H synthase 2 (COX-2) TTVKILB PGH2_HUMAN Inhibitor [6]
------------------------------------------------------------------------------------
Celecoxib Interacts with 5 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [7]
Sulfotransferase 1A1 (SULT1A1) DEYWLRK ST1A1_HUMAN Metabolism [8]
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Metabolism [9]
Cytochrome P450 2C8 (CYP2C8) DES5XRU CP2C8_HUMAN Metabolism [10]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Metabolism [11]
------------------------------------------------------------------------------------
Indication(s) of Moxifloxacin
Disease Entry ICD 11 Status REF
Bacterial infection 1A00-1C4Z Approved [4]
Mycoplasma pneumoniae pneumonia N.A. Approved [5]
Peritonitis N.A. Approved [5]
Pneumonic plague N.A. Approved [5]
Septicemic plague N.A. Approved [5]
Staphylococcal pneumonia N.A. Approved [5]
Staphylococcus aureus infection N.A. Approved [5]
Streptococcal pneumonia N.A. Approved [5]
Tuberculosis 1B10-1B14 Approved [5]
Pneumonia caused by chlamydia N.A. Investigative [5]
Pneumonia due to Klebsiella pneumoniae CA40.03 Investigative [5]
Moxifloxacin Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Bacterial DNA gyrase (Bact gyrase) TTN6J5F GYRA_STAAU; GYRB_STAAU Modulator [12]
Staphylococcus Topoisomerase IV (Stap-coc parC) TTIXTO3 PARC_STAAS Modulator [12]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT03822520) Clinical Study to Evaluate Effect on QT/QTc Interval After Multiple Dose of Celecoxib
2 Celecoxib FDA Label
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2892).
4 Novel agents in the management of Mycobacterium tuberculosis disease. Curr Med Chem. 2007;14(18):2000-8.
5 Moxifloxacin FDA Label
6 Pfizer. Product Development Pipeline. March 31 2009.
7 Major role of human liver microsomal cytochrome P450 2C9 (CYP2C9) in the oxidative metabolism of celecoxib, a novel cyclooxygenase-II inhibitor. J Pharmacol Exp Ther. 2000 May;293(2):453-9.
8 Sulfonation of 17beta-estradiol and inhibition of sulfotransferase activity by polychlorobiphenylols and celecoxib in channel catfish, Ictalurus punctatus. Aquat Toxicol. 2007 Mar 10;81(3):286-92.
9 Celecoxib is a substrate of CYP2D6: impact on celecoxib metabolism in individuals with CYP2C9*3 variants. Drug Metab Pharmacokinet. 2018 Oct;33(5):219-227.
10 Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies. Pharmacogenomics. 2009 Sep;10(9):1489-510.
11 Drug interactions in dentistry: the importance of knowing your CYPs. J Am Dent Assoc. 2004 Mar;135(3):298-311.
12 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.